Absolute number of HIV-1- and CMV-specific single IFN-γ, IL-2/IFN-γ, and single IL-2-secreting CD4 T cells
. | CD4 T cells/μL . | IFN-γ . | IL-2/IFN-γ . | IL-2 . |
|---|---|---|---|---|
| HIV-1-p55 stimulation | ||||
| Progressors BSL, n = 8 | 739 ± 111 | 0.8 ± 0.24 (0.12) | 0.13 ± 0.03 (0.02) | 0.18 ± 0.043 (0.03) |
| After ART, n = 8 | 1004 ± 108 | 0.42 ± 0.1 (0.04) | 0.21 ± 0.04 (0.02) | 0.4 ± 0.07 (0.04) |
| LTNPs, n = 5 | 960 ± 186 | 1.41 ± 0.6 (0.12) | 0.63 ± 0.15 (0.07) | 1.08 ± 0.4 (0.1) |
| CMV stimulation | ||||
| Progressors BSL, n = 5 | 739 ± 111 | 2.25 ± 0.96 (0.24) | 1.60 ± 0.84 (0.17) | 0.7 ± 0.24 (0.08) |
| After ART, n = 5 | 1004 ± 108 | 1.92 ± 0.85 (0.16) | 1.58 ± 1.06 (0.14) | 0.87 ± 0.29 (0.08) |
| LTNPs, n = 5 | 960 ± 186 | 4.70 ± 3.47 (0.36) | 2.70 ± 1.48 (0.24) | 1.51 ± 0.61 (0.13) |
. | CD4 T cells/μL . | IFN-γ . | IL-2/IFN-γ . | IL-2 . |
|---|---|---|---|---|
| HIV-1-p55 stimulation | ||||
| Progressors BSL, n = 8 | 739 ± 111 | 0.8 ± 0.24 (0.12) | 0.13 ± 0.03 (0.02) | 0.18 ± 0.043 (0.03) |
| After ART, n = 8 | 1004 ± 108 | 0.42 ± 0.1 (0.04) | 0.21 ± 0.04 (0.02) | 0.4 ± 0.07 (0.04) |
| LTNPs, n = 5 | 960 ± 186 | 1.41 ± 0.6 (0.12) | 0.63 ± 0.15 (0.07) | 1.08 ± 0.4 (0.1) |
| CMV stimulation | ||||
| Progressors BSL, n = 5 | 739 ± 111 | 2.25 ± 0.96 (0.24) | 1.60 ± 0.84 (0.17) | 0.7 ± 0.24 (0.08) |
| After ART, n = 5 | 1004 ± 108 | 1.92 ± 0.85 (0.16) | 1.58 ± 1.06 (0.14) | 0.87 ± 0.29 (0.08) |
| LTNPs, n = 5 | 960 ± 186 | 4.70 ± 3.47 (0.36) | 2.70 ± 1.48 (0.24) | 1.51 ± 0.61 (0.13) |
The absolute number of cytokine-secreting cells was calculated from the CD4 T-cell counts. Data are presented as mean ± SE, and values in parentheses represent the mean percentage of cytokine-secreting cells in CD4 T cells. BSL indicates baseline; ART, antiretroviral therapy; and LTNPs, long-term nonprogressors.